GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qlife Holding AB (FRA:4HG) » Definitions » ROCE %

Qlife Holding AB (FRA:4HG) ROCE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Qlife Holding AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Qlife Holding AB's annualized ROCE % for the quarter that ended in Mar. 2024 was 0.00%.


Qlife Holding AB ROCE % Historical Data

The historical data trend for Qlife Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qlife Holding AB ROCE % Chart

Qlife Holding AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
- -53.06 -46.17 -67.39 -248.74

Qlife Holding AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.00 -77.17 -46.51 -1,106.40 -

Qlife Holding AB ROCE % Calculation

Qlife Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-14.059/( ( (17.524 - 4.84) + (3.491 - 4.871) )/ 2 )
=-14.059/( (12.684+-1.38)/ 2 )
=-14.059/5.652
=-248.74 %

Qlife Holding AB's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-4.432/( ( (3.491 - 4.871) + (3.97 - 4.305) )/ 2 )
=-4.432/( ( -1.38 + -0.335 )/ 2 )
=-4.432/-0.8575
=0 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Qlife Holding AB  (FRA:4HG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Qlife Holding AB ROCE % Related Terms

Thank you for viewing the detailed overview of Qlife Holding AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Qlife Holding AB (FRA:4HG) Business Description

Traded in Other Exchanges
Address
Redaregatan 48, Helsingborg, SWE, SE-252 36
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.

Qlife Holding AB (FRA:4HG) Headlines

No Headlines